BioNano Genomics Inc vs The Coca-Cola Co K — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while The Coca-Cola Co K trades at $83.2 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 27079.5× BioNano Genomics Inc's market cap, and The Coca-Cola Co K pays a 2.55% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KO | |
|---|---|---|
Market Cap | $13.20M | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $84.25 |
52-Week Low | $1.09 | $65.67 |
Enterprise Value | $15.81M | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 27.8% net margin and 45.8% ROE, though valuation multiples like P/E of 26.5 appear elevated. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
The outlook remains positive with a $89.75 analyst target suggesting 6.5% upside, supported by dividend reliability. Key risks include high debt levels and regional demand volatility. The stock presents a steady growth opportunity with moderate upside potential balanced by valuation concerns.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →